Veterans

This report summarises what Blossom’s database shows about psychedelic research in and for military veterans, and what it does not show. The short version: veterans carry a heavy, often treatment-resistant burden of PTSD, depression, traumatic brain injury and suicidality, which has made them central to psychedelic science and to a remarkable real-world demand. The early signals are genuinely encouraging. They are also mostly uncontrolled, the durability is shakier than the headlines, and in 2024 the most advanced programme, MDMA for PTSD, was rejected by the FDA. Both halves of that matter.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Psychedelics are being studied in veterans; with the partial exception of esketamine for treatment-resistant depression, they are not approved treatments for these conditions, and several carry real risks. If you are a veteran or care for one, decisions about treatment belong with a qualified clinician, and travelling abroad for unregulated treatment carries safety and legal risks worth taking seriously.

One framing point on the numbers. Blossom currently tracks 51 papers and 31 trials tagged to this topic, and those counts appear on this page. They are broader than they look: the tag is leaky, pulling in cost-effectiveness models, ethics statements, mixed civilian-and-veteran retreat studies and even military drug-research history. The genuinely veteran-treatment core is a smaller subset, and the rigorously controlled part of it is a handful of trials. Read the counts as database coverage, not as a tally of proven veteran treatments.

Why are veterans central to psychedelic research?

The simplest answer is unmet need. Veterans develop PTSD, depression, traumatic brain injury and chronic pain at higher rates than civilians, and the VA estimates around 7 in 100 veterans will have PTSD in their lifetime[1]VA National Center for PTSD, far more after combat, while veteran suicide stays well above the civilian rate. First-line treatments, trauma-focused therapy and antidepressants, help many but leave a large minority symptomatic, and dropout is high.

That gap has made veterans both a priority population for formal trials and the engine of a grassroots movement. The result is a literature with an unusual shape: a few rigorous trials sitting alongside a large body of open-label pilots, retreats and treatment-abroad cohorts, all pointing at the same desperate need from very different levels of evidence. It is also a population whose suffering is bound up with identity, duty and a sense that the institutions meant to help fell short, which is part of why interest in these treatments runs so high, and why the honesty of how they are described matters so much.

MDMA and PTSD: large effects, and a regulatory rejection

MDMA-assisted therapy is where the controlled veteran evidence is strongest and where the field hit its hardest wall. A randomised Phase 2 dose-response trial in 26 veterans, firefighters and police[2]Lancet Psychiatry (2018) reported a very large PTSD reduction at the 75 mg dose, a pooled analysis of six Phase 2 trials[3]Psychopharmacology (2020) found benefits that held to a year, and a meta-analysis put the pooled effect at a large magnitude[4]Prog. Neuro-Psychopharmacol. Biol. Psychiatry (2020) while rating the underlying trials only moderate in quality.

Then, in August 2024, the FDA declined to approve MDMA-assisted therapy for PTSD[5]FDA Complete Response Letter, Aug 2024, issuing a Complete Response Letter and requesting an additional Phase 3 study. The decision crystallised the field’s structural weakness: because MDMA produces unmistakable effects, participants and therapists usually know who received it, so functional unblinding can inflate apparent benefit, and the programme also drew scrutiny over trial conduct. The proposed mechanism, oxytocin release and a shift in fear processing that eases emotional engagement[6]J. Psychopharmacology (2009), is plausible and supported by imaging, but a plausible mechanism is not a regulatory approval.

Ketamine: clear for depression, unclear for PTSD

Ketamine is the most-used compound in veteran care and the most instructive. For depression it performs well: a dose-finding RCT in veterans with late-life treatment-resistant depression[7]Neuropsychopharmacology (2021) showed strong, sustained response, and repeated infusions help veterans with comorbid PTSD and depression, though the effect relapses within weeks[8]J. Clinical Psychiatry (2018).

For PTSD the story is more sobering. The single largest, best-controlled veteran trial, a multi-site RCT in 158 veterans and service members, found no PTSD benefit over placebo[9]Neuropsychopharmacology (2022), even though it improved depression. That negative result sits in direct tension with smaller, uncontrolled combat-veteran series reporting big drops[10]Innov. Clin. Neurosci. (2019), and it is the cleanest illustration on this page of why open-label success is not proof.

Psilocybin: a promising signal that wanes

Psilocybin in veterans is early and honest about its own limits. The first open-label pilot in 15 veterans with severe treatment-resistant depression[11]J. Affective Disorders (2025) reported 60% response and 53% remission at three weeks, a striking result for a single dose. But the 12-month follow-up showed the antidepressant effect beginning to wane by six months[12]J. Affective Disorders (2025), with response down to 40% at a year.

A separate uncontrolled psilocybin retreat in 21 veterans with a history of TBI[13]Front. Psychiatry (2025) reported large symptom reductions and EEG changes, and veteran PTSD trials of psilocybin are mostly still recruiting. A recurring and useful finding across these pilots is that the intensity of the acute psychedelic experience did not predict who got better, which complicates the popular idea that the subjective "trip" is the active ingredient.

Ibogaine, 5-MeO-DMT and the journey abroad

The most distinctive veteran story in this database is not a trial at all: it is the movement of Special Operations veterans who travel to clinics in Mexico for ibogaine, often followed by 5-MeO-DMT. A retrospective survey of 51 such veterans[14]Chronic Stress (2020) reported very large before-after reductions in suicidal ideation, PTSD and depression; a larger prospective follow-up of 86 veterans[15]Am. J. Drug & Alcohol Abuse (2023) found the same direction of effect, and a subset with risky drinking mostly returned to non-risky levels within a month[16]Military Psychology (2023).

These numbers are the largest on the page and rest on the weakest designs: retrospective, self-selected, self-funded, unblinded, no control group. They are best read as powerful evidence of unmet need and self-reported relief, not as proof of efficacy. The most rigorous ibogaine work, the Stanford open-label study of magnesium-ibogaine in 30 veterans with TBI[17]Nature Medicine (2024), is more credible but still single-arm, and even there the mystical intensity of the experience tracked with PTSD improvement[18]J. Affective Disorders (2026), the opposite of the psilocybin finding above, leaving the mechanism genuinely open. Ibogaine’s risk of fatal cardiac arrhythmia is real, which is why magnesium is co-administered. Two further cautions belong here: the most-cited cohort is almost entirely white, male Special Operations veterans, so even its self-reported benefits may not carry over to the broader, more diverse veteran population, and ibogaine remains illegal in the United States, which is why this treatment happens abroad in the first place.

Substance use and suicidality

Substance use and suicidality run through the veteran story, and the data follow the same pattern: striking but uncontrolled. In the Special Operations cohorts treated abroad, a subset with risky drinking mostly returned to non-risky levels within a month[16]Military Psychology (2023), and the same surveys reported large reductions in suicidal ideation[14]Chronic Stress (2020) alongside the PTSD and depression changes. The honest reading is that these compounds may help the addiction and despair that so often accompany veteran trauma, but the evidence is self-reported and uncontrolled, and nothing here establishes that they reduce suicide risk in the way a controlled trial would need to show. For a population with an elevated suicide rate, that distinction is not academic.

Moral injury and the gaps

Moral injury, the lasting harm of having done or witnessed something that violates one’s deepest values, is central to how many veterans describe their suffering, yet it is almost absent as a measured outcome in this database. Only one trial names it explicitly, and no completed study reports a moral-injury endpoint. It is an honest gap worth stating plainly: the concept that may matter most to veterans is the one the evidence has barely touched.

The trial pipeline

The forward signal is a broad pipeline: a Phase 3 psilocybin study for veteran treatment-resistant depression, multiple MDMA trials in group and massed-exposure formats, ketamine studies for comorbid pain and depression, and the magnesium-ibogaine line for TBI, with the VA increasingly funding and hosting the work. The honest counterweight is attrition: several MDMA-in-veterans trials have been terminated or withdrawn, a few are of unknown status, and the most rigorous ketamine PTSD trial was negative. A wide pipeline is a sign of momentum, not of settled answers.

Reading this honestly

So where does that leave a veteran, a clinician or a policymaker reading this? The substance is real: a population with enormous unmet need, large early effects for MDMA, solid depression results for ketamine, an encouraging psilocybin signal, and a grassroots movement that has surfaced genuine reported relief. The hype is anything implying proven, approved, durable cures. The most advanced programme was rejected, the best-controlled PTSD trial was negative, the psilocybin benefit fades, and the most dramatic numbers are uncontrolled. Taking the promise seriously while refusing to overstate it is the honest position, and for a population this vulnerable, it is the only responsible one.